Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Jeong-Ju Seo"'
Autor:
Jeonghyeon Park, Keumhan Noh, Hae Won Lee, Mi-sun Lim, Sook Jin Seong, Jeong Ju Seo, Eun-Jung Kim, Wonku Kang, Young-Ran Yoon
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60556 (2013)
Drug-induced torsades de pointes (TdP), a life-threatening arrhythmia associated with prolongation of the QT interval, has been a significant reason for withdrawal of several medicines from the market. Prolongation of the QT interval is considered as
Externí odkaz:
https://doaj.org/article/70eb200070e649e286ddac34af3efa88
Publikováno v:
2020 International Conference on Electronics, Information, and Communication (ICEIC).
In this paper, we propose a Lateral insulated-gate bipolar transistor (LIGBT) based device using stack technology for electrostatic discharge (ESD) protection. This new ESD surge protection device inserts a floating N + region into the N-Well of a co
Publikováno v:
EECS
In this paper, we proposed a new silicon controlled rectifier (SCR)-based protection device using a triple-well structure. The proposed protection device has higher holding voltage and lower trigger voltage than conventional ESD protection device. Th
Autor:
Jeong Ju Seo, JinShil Kim, Sung Yong Oh, Ja Youn Lee, Keon Uk Park, Bhumsuk Keam, Min Kyung Hyun, Jinseok Ahn, Su-Jin Koh
Publikováno v:
Pain medicine (Malden, Mass.). 19(12)
Objectives More than half of the patients have reported improper management of breakthrough cancer pain. Empirical evidence is lacking concerning the effectiveness of cancer pain education on breakthrough pain control. This study aimed to examine the
Autor:
Jin Seok Ahn, Yeon Hee Park, Young-Hyuck Im, Ji-Yeon Kim, Jeong-Ju Seo, Soo-Hyeon Lee, Oh Nam Ok
Publikováno v:
Breast cancer research and treatment. 164(3)
Onycholysis and other nail toxicities occur in approximately 20–30% of breast cancer (BC) patients receiving docetaxel chemotherapy. Onycholysis is often associated with painful paronychia, decreasing patients’ quality of life. In this study, we
Autor:
Jeong Ju Seo, Hae Won Lee, Sook Jin Seong, Sung Min Park, Jeonghyeon Park, Young-Ran Yoon, Min Ho Bae, Mi-sun Lim, Joomi Lee
Publikováno v:
Journal of Chromatography B. :38-42
A sensitive and simple detection method coupling ultra-performance liquid chromatography with tandem mass spectrometry was developed and validated to analyze sumatriptan levels in human plasma. The plasma sample preparations for the analysis were bas
Autor:
Young-Ran Yoon, Jeonghyeon Park, Jeong Ju Seo, Mi-sun Lim, Joomi Lee, Sook Jin Seong, Hae Won Lee, Sung Min Park
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 8:921-928
The aim of this study was to investigate the pharmacokinetics and dose proportionality of a single, intravenous dose of pazufloxacin mesilate, an injectable fluoroquinolone antibiotic, in healthy Korean male volunteers.In this open-label, four-dose,
Autor:
Young-Ran Yoon, Jeonghyeon Park, Mi-sun Lim, Joomi Lee, Jeong Ju Seo, Hae Won Lee, Kyung Sang Yu, Sook Jin Seong
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 8:399-405
Levofloxacin and cyclosporine show different pharmacokinetic properties, but are known to be dose proportional within the therapeutic range. The authors evaluated the pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold do
Autor:
Jeonghyeon Park, Jeong Ju Seo, Mi-sun Lim, Joomi Lee, Sook Jin Seong, Young-Ran Yoon, Kwang-il Kwon, In-hwan Baek, Hwi-yeol Yun, Hae Won Lee
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 7:1471-1479
An enteric-coated formulation of triflusal (triflusal EC), an antiplatelet agent, was developed to reduce the high incidence of gastrointestinal adverse events (AEs). The aim of this study is to compare the pharmacokinetics, pharmacodynamics and safe
Autor:
Mi-sun Lim, Hae Won Lee, Kyung Sang Yu, Jeonghyeon Park, Sook Jin Seong, Joomi Lee, Joo Youn Cho, Jeong Ju Seo, Young-Ran Yoon
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 7:1337-1344
The aim of this study was to compare the pharmacokinetics (PK) and safety of fimasartan (BR-A-657), an angiotensin II receptor antagonist, between healthy young (19 - 45 years) and older (≥ 65 years) male subjects.To assess the effect of age on PK